Lipocine financials
$2.16+3.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | -$2.9M | $500.0K | $16.1M | $0.00 | $165.0K | $428.0K | $0.00 | $0.00 |
| Gross profit | $2.0M | $11.2M | -$2.9M | $500.0K | $16.1M | $0.00 | $165.0K | $428.0K | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | — | — |
| Operating income | -$10.4M | -$1.2M | -$17.9M | -$11.9M | -$854.5K | -$18.0M | -$12.9M | -$11.3M | -$21.2M | -$19.2M |
| Net income | -$9.6M | $8.4K | -$16.4M | -$10.8M | -$634.4K | -$21.0M | -$13.0M | -$11.7M | -$21.0M | -$19.0M |
| Net margin | −487.1% | 0.1% | 573.6% | −2151.7% | −3.9% | — | −7883.7% | −2724.1% | — | — |
| Diluted EPS | $-1.69 | $0.00 | $-3.14 | $-2.15 | $-0.17 | $-6.46 | $-8.50 | $-9.35 | $-17.85 | $-17.68 |
| EBITDA | -$10.3M | -$1.1M | -$17.9M | -$12.1M | $3.1M | -$18.0M | -$12.9M | -$11.3M | -$21.2M | -$18.4M |
| Operating cash flow | -$9.8M | -$1.2M | -$11.9M | -$12.0M | -$4.4M | -$15.3M | -$11.7M | -$12.1M | -$16.7M | -$18.3M |
| Free cash flow | -$9.8M | -$1.3M | -$11.9M | -$12.1M | -$4.4M | -$15.3M | — | — | -$16.7M | -$18.3M |
| Diluted shares | 5.7M | 5.4M | 5.3M | 5.3M | 5.2M | 3.3M | 1.5M | 1.3M | 1.2M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.2M | $6.2M | $4.8M | $3.1M | $3.0M | $19.2M |
| Short-term investments | $9.7M | $15.4M | $17.3M | $29.4M | $41.7M | $450.0K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $2.3M | $5.6M |
| Total assets | $17.0M | $22.5M | $23.0M | $37.5M | $52.5M | $25.4M |
| Total liabilities | $2.5M | $1.5M | $2.6M | $1.9M | $6.1M | $8.8M |
| Shareholders' equity | $14.5M | $21.0M | $20.4M | $35.6M | $46.4M | $16.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology